Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference
22 mai 2018 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 22, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2018 Healthcare Conference
10 mai 2018 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 10, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care Conference
04 mai 2018 16h01 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results
02 mai 2018 07h40 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 02, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid
02 mai 2018 07h30 HE
|
Esperion Therapeutics, Inc.
— Met Primary Endpoint of Safety and Tolerability in Largest and Longest Duration Study —— Bempedoic Acid Achieved Additional 20% On-Treatment LDL-C Lowering on Background Maximally Tolerated Statin...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
13 avr. 2018 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 13, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia
27 mars 2018 07h30 HE
|
Esperion Therapeutics, Inc.
— Study Met Primary Endpoint with 30% Additional LDL-C Lowering — — hsCRP Reduction of 34% — — Observed to be Safe and Well-Tolerated in This Study — — Conference Call and Webcast on Tuesday, March...
Esperion to Participate in Fireside Chat at March 2018 Investor Conferences
07 mars 2018 16h01 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., March 07, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...
Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid
07 mars 2018 07h30 HE
|
Esperion Therapeutics, Inc.
— Study 4 Met Primary Endpoint with 28% Additional LDL-C Lowering on Background Ezetimibe and Up to the Lowest Daily Dose of a Statin — — hsCRP Reduction of 33% — — Observed to be Safe and...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
23 févr. 2018 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Feb. 23, 2018 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective,...